BACKGROUND: Multiple lines of research suggest that increased cystatin C activity in the brain protects against the development of Alzheimer disease (AD). METHODS: Serum cystatin C levels were analyzed at two examinations of the Uppsala Longitudinal Study of Adult Men, a longitudinal, community-based study of elderly men (age 70 years, n = 1,153 and age 77 years, n = 761, a subset of the age 70 examination). Cox regressions were used to examine associations between serum cystatin C and incident AD. AD cases were identified by cognitive screening and comprehensive medical chart review in all subjects. RESULTS: On follow-up (median 11.3 years), 82 subjects developed AD. At age 70 years, lower cystatin C was associated with higher risk of AD independently of age, APOE4 genotype, glomerular filtration rate, diabetes, hypertension, stroke, cholesterol, body mass index, smoking, education level, and plasma amyloid-beta protein 40 and 42 levels (hazard ratio [HR] for lowest [<1.12 micromol/L] vs highest [>1.30 micromol/L] tertile = 2.67, 95% CI 1.22-5.83, p < 0.02). The results were similar at age 77 years (43 participants developed AD during follow-up). Furthermore, a 0.1-mumol/L decrease of cystatin C between ages 70 and 77 years was associated with a 29% higher risk of incident AD (HR 1.29, 95% CI 1.03-1.63, p < 0.03). CONCLUSIONS: Low levels of serum cystatin C precede clinically manifest Alzheimer disease (AD) in elderly men free of dementia at baseline and may be a marker of future risk of AD. These findings strengthen the evidence for a role for cystatin C in the development of clinical AD.
BACKGROUND: Multiple lines of research suggest that increased cystatin C activity in the brain protects against the development of Alzheimer disease (AD). METHODS: Serum cystatin C levels were analyzed at two examinations of the Uppsala Longitudinal Study of Adult Men, a longitudinal, community-based study of elderly men (age 70 years, n = 1,153 and age 77 years, n = 761, a subset of the age 70 examination). Cox regressions were used to examine associations between serum cystatin C and incident AD. AD cases were identified by cognitive screening and comprehensive medical chart review in all subjects. RESULTS: On follow-up (median 11.3 years), 82 subjects developed AD. At age 70 years, lower cystatin C was associated with higher risk of AD independently of age, APOE4 genotype, glomerular filtration rate, diabetes, hypertension, stroke, cholesterol, body mass index, smoking, education level, and plasma amyloid-beta protein 40 and 42 levels (hazard ratio [HR] for lowest [<1.12 micromol/L] vs highest [>1.30 micromol/L] tertile = 2.67, 95% CI 1.22-5.83, p < 0.02). The results were similar at age 77 years (43 participants developed AD during follow-up). Furthermore, a 0.1-mumol/L decrease of cystatin C between ages 70 and 77 years was associated with a 29% higher risk of incident AD (HR 1.29, 95% CI 1.03-1.63, p < 0.03). CONCLUSIONS: Low levels of serum cystatin C precede clinically manifest Alzheimer disease (AD) in elderly men free of dementia at baseline and may be a marker of future risk of AD. These findings strengthen the evidence for a role for cystatin C in the development of clinical AD.
Authors: E Levy; M D Carman; I J Fernandez-Madrid; M D Power; I Lieberburg; S G van Duinen; G T Bots; W Luyendijk; B Frangione Journal: Science Date: 1990-06-01 Impact factor: 47.728
Authors: Elisabetta Straface; Paola Matarrese; Lucrezia Gambardella; Rosa Vona; Antonio Sgadari; Maria Caterina Silveri; Walter Malorni Journal: FEBS Lett Date: 2005-04-19 Impact factor: 4.124
Authors: Yelena Slinin; Katherine W Peters; Areef Ishani; Kristine Yaffe; Howard A Fink; Katie L Stone; Michael Steffes; Kristine E Ensrud Journal: J Gerontol A Biol Sci Med Sci Date: 2014-11-01 Impact factor: 6.053
Authors: Brendan Darsie; Michael G Shlipak; Mark J Sarnak; Ronit Katz; Annette L Fitzpatrick; Michelle C Odden Journal: Am J Epidemiol Date: 2014-05-20 Impact factor: 4.897
Authors: Kristine Yaffe; Manjula Kurella-Tamura; Lynn Ackerson; Tina D Hoang; Amanda H Anderson; Mark Duckworth; Alan S Go; Marie Krousel-Wood; John W Kusek; James P Lash; Akinlolu Ojo; Nancy Robinson; Ashwini R Sehgal; James H Sondheimer; Susan Steigerwalt; Raymond R Townsend Journal: J Am Geriatr Soc Date: 2014-08-14 Impact factor: 5.562
Authors: Lana Sargent; Mike Nalls; Angela Starkweather; Sarah Hobgood; Holly Thompson; Elaine J Amella; Andrew Singleton Journal: Ageing Res Rev Date: 2018-08-10 Impact factor: 10.895